AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 140 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $45,178 | +101.7% | 2,986 | 0.0% | 0.00% | +100.0% |
Q2 2022 | $22,395 | -17.6% | 2,986 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $27,173 | -67.0% | 2,986 | -74.6% | 0.00% | 0.0% |
Q4 2021 | $82,450 | -38.6% | 11,745 | -0.3% | 0.00% | -50.0% |
Q3 2021 | $134,315 | -28.8% | 11,782 | 0.0% | 0.00% | -33.3% |
Q2 2021 | $188,630 | -4.6% | 11,782 | +6.4% | 0.00% | 0.0% |
Q1 2021 | $197,821 | +19.9% | 11,070 | -9.3% | 0.00% | +50.0% |
Q4 2020 | $164,971 | +7.7% | 12,211 | -6.1% | 0.00% | -33.3% |
Q3 2020 | $153,128 | -26.2% | 13,010 | -7.5% | 0.00% | -25.0% |
Q2 2020 | $207,585 | +9.3% | 14,064 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $189,864 | -44.1% | 14,064 | 0.0% | 0.00% | -33.3% |
Q4 2019 | $339,927 | +25.8% | 14,064 | 0.0% | 0.01% | +20.0% |
Q3 2019 | $270,310 | -24.5% | 14,064 | +16.2% | 0.01% | -16.7% |
Q2 2019 | $357,791 | -34.9% | 12,108 | +4.6% | 0.01% | -40.0% |
Q1 2019 | $549,860 | +31.6% | 11,576 | 0.0% | 0.01% | +25.0% |
Q4 2018 | $417,894 | -41.3% | 11,576 | 0.0% | 0.01% | -38.5% |
Q3 2018 | $712,503 | -99.9% | 11,576 | 0.0% | 0.01% | 0.0% |
Q2 2018 | $781,959,000 | +34.7% | 11,576 | +8.2% | 0.01% | +62.5% |
Q1 2018 | $580,421,000 | +91884.3% | 10,699 | +1.4% | 0.01% | 0.0% |
Q4 2017 | $631,000 | -40.6% | 10,555 | -51.7% | 0.01% | +14.3% |
Q3 2017 | $1,062,000 | -2.5% | 21,844 | +5.4% | 0.01% | -12.5% |
Q2 2017 | $1,089,000 | +15.9% | 20,721 | 0.0% | 0.01% | +14.3% |
Q1 2017 | $940,000 | +19.9% | 20,721 | 0.0% | 0.01% | +16.7% |
Q4 2016 | $784,000 | +16.1% | 20,721 | +15.8% | 0.01% | +20.0% |
Q3 2016 | $675,000 | +114.3% | 17,893 | 0.0% | 0.01% | +150.0% |
Q2 2016 | $315,000 | +68.4% | 17,893 | +16.6% | 0.00% | +100.0% |
Q1 2016 | $187,000 | -50.0% | 15,349 | 0.0% | 0.00% | -66.7% |
Q4 2015 | $374,000 | +37.5% | 15,349 | 0.0% | 0.00% | +50.0% |
Q3 2015 | $272,000 | +0.4% | 15,349 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $271,000 | +2.7% | 15,349 | +70.0% | 0.00% | 0.0% |
Q4 2014 | $264,000 | +41.2% | 9,028 | 0.0% | 0.00% | +100.0% |
Q3 2014 | $187,000 | -11.8% | 9,028 | +5.5% | 0.00% | 0.0% |
Q2 2014 | $212,000 | – | 8,558 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |